Hikal

₹283.5 -3.7 | 1.3%

WEBSITE BSE:524735 NSE : HIKAL LTD. 10 May, 16:01

Market Cap ₹3495 Cr.

Stock P/E 50.2

P/B 2.9

Current Price ₹283.5

Book Value ₹ 96.3

Face Value 2

52W High ₹331.1

Dividend Yield 0.42%

52W Low ₹ 258.6

Edit Ratio

Hikal Research see more...

Overview Inc. Year: 1988Industry: Pharmaceuticals & Drugs

Hikal Ltd is in the manufacturing of various chemical intermediates, active pharmaceutical elements (APIs), contract research activities and speciality chemical substances. The Company offers prescribed drugs and agrochemicals. Its segments comprises Crop Protection and Pharmaceuticals. It offers agrochemicals, inclusive of active elements, such as Ammonium dithiocarbamate, Amitrole Tech, Diuron Tech, Ethion Tech, Imazalil Tech, Isoproturon Tech, Meta chloro Aniline (MCA), Quinalphos Tech and Temephos Tech, and intermediates and distinctiveness chemical compounds, which include Phenyl-2-(phenylthio)-phenyl carbamate, 4-(Benzyloxy) Aniline Hydrochloride, N-Benzylpiperidine-4-carboxaldehyde, three-Chloroaniline and four Aminobenzylamine. Its APIs include Levetiracetam, Quetiapine Fumarate, Memantine Hydrochloride, Gabapentin, Pregabalin, Venlafaxine Hydrochloride and Donepezil Hydrochloride. The Company operates in geographical regions, which include India, Europe, the US, Canada and South East Asia.

Hikal Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Hikal Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	515	502	379	559	540	545	388	435	448	514
Other Income	1	0	3	1	3	0	1	1	0	0
Total Income	515	503	382	560	543	546	389	436	448	515
Total Expenditure	422	441	356	489	466	457	338	377	383	420
Operating Profit	93	61	26	71	77	88	51	59	65	95
Interest	7	8	11	11	13	13	14	13	14	15
Depreciation	25	24	27	27	28	27	28	29	29	32
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	62	29	-12	33	36	49	10	17	22	47
Provision for Tax	16	8	-3	8	9	13	3	4	5	13
Profit After Tax	45	21	-9	25	26	36	7	13	16	34
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	45	21	-9	25	26	36	7	13	16	34
Adjusted Earnings Per Share	3.7	1.7	-0.7	2	2.1	2.9	0.6	1	1.3	2.8

Hikal Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	660	829	872	926	1014	1296	1590	1507	1720	1943	2023	1785
Other Income	6	34	2	2	3	4	2	4	5	5	5	2
Total Income	667	863	873	927	1017	1301	1592	1511	1725	1948	2028	1788
Total Expenditure	476	642	689	745	815	1054	1291	1234	1398	1602	1766	1518
Operating Profit	190	221	184	183	202	246	300	277	328	345	262	270
Interest	60	68	60	62	48	49	58	52	36	31	48	56
Depreciation	49	55	64	67	69	86	93	82	85	96	109	118
Exceptional Income / Expenses	-48	0	0	0	-4	0	0	-15	0	0	0	0
Profit Before Tax	33	98	60	53	80	111	149	127	206	219	105	96
Provision for Tax	8	34	19	12	13	34	46	42	73	58	27	25
Profit After Tax	25	64	40	41	68	77	103	84	133	160	78	70
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	25	64	40	41	68	77	103	84	133	160	78	70
Adjusted Earnings Per Share	2	5.2	3.3	3.3	5.5	6.3	8.4	6.8	10.8	13	6.4	5.7

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	4%	10%	9%	12%
Operating Profit CAGR	-24%	-2%	1%	3%
PAT CAGR	-51%	-2%	0%	12%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-4%	-6%	10%	16%
ROE Average	7%	13%	13%	12%
ROCE Average	8%	13%	14%	13%

Hikal Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	450	505	532	564	605	669	756	817	933	1068	1133
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	220	255	201	297	320	297	298	303	263	287	490
Other Non-Current Liabilities	18	43	40	40	4	15	62	107	116	145	157
Total Current Liabilities	503	479	530	397	470	616	659	653	703	828	691
Total Liabilities	1191	1282	1304	1298	1399	1597	1775	1879	2016	2328	2471
Fixed Assets	660	644	639	623	668	634	713	735	713	879	948
Other Non-Current Assets	121	131	152	185	124	218	175	313	378	425	554
Total Current Assets	409	507	513	490	607	746	886	831	925	1023	968
Total Assets	1191	1282	1304	1298	1399	1597	1775	1879	2016	2328	2471

Hikal Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	3	9	16	6	4	2	6	11	32	8	11
Cash Flow from Operating Activities	61	154	102	186	163	139	186	285	229	294	315
Cash Flow from Investing Activities	-28	-23	-43	-64	-102	-110	-125	-164	-156	-284	-292
Cash Flow from Financing Activities	-27	-124	-69	-124	-63	-25	-55	-101	-97	-6	-8
Net Cash Inflow / Outflow	6	7	-10	-2	-2	4	6	20	-24	4	15
Closing Cash & Cash Equivalent	9	16	6	4	2	6	11	32	8	11	27

Hikal Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	2.05	5.18	3.28	3.34	5.49	6.26	8.36	6.85	10.8	13.02	6.36
CEPS(Rs)	6.03	9.65	8.48	8.8	11.1	13.21	15.89	13.54	17.71	20.78	15.2
DPS(Rs)	0.5	0.9	1	1	1.2	1.2	1.2	1.2	2	1.6	1.2
Book NAV/Share(Rs)	27.77	32.25	34.56	37.16	49.07	54.29	61.33	66.22	75.7	86.62	91.93
Core EBITDA Margin(%)	27.69	22.42	20.79	19.33	19.19	18.59	18.75	18.12	18.77	17.53	12.71
EBIT Margin(%)	13.98	19.91	13.65	12.34	12.43	12.35	13.05	11.88	14.1	12.86	7.59
Pre Tax Margin(%)	4.97	11.76	6.81	5.69	7.76	8.58	9.38	8.4	12	11.25	5.21
PAT Margin (%)	3.8	7.66	4.6	4.4	6.55	5.94	6.48	5.6	7.74	8.26	3.87
Cash Profit Margin (%)	11.17	14.25	11.92	11.6	13.24	12.52	12.33	11.07	12.69	13.19	9.26
ROA(%)	2.17	5.17	3.12	3.17	5.02	5.15	6.11	4.62	6.84	7.39	3.27
ROE(%)	7.6	17.27	9.81	9.32	12.74	12.12	14.46	10.74	15.22	16.04	7.12
ROCE(%)	10.44	17.77	12.5	11.92	11.87	12.81	15.25	12.44	16.15	15.21	8.47
Receivable days	51.2	37.91	45.07	46.88	65.09	76.34	73.14	83.56	87.62	86.73	79.34
Inventory Days	123.43	124.28	130.03	118.04	97.91	79.54	76.61	81.93	61.44	55.96	58.25
Payable days	158.83	118.48	114.68	104.06	92.64	77.03	69.37	84.9	86.55	87.68	92.7
PER(x)	26.08	12.1	28.24	23.38	25.83	21.87	20.93	10.22	13.29	30.92	44.34
Price/Book(x)	1.92	1.95	2.68	2.1	2.89	2.52	2.85	1.06	1.9	4.65	3.07
Dividend Yield(%)	0.62	0.96	0.72	0.85	0.56	0.58	0.69	1.71	1.39	0.4	0.43
EV/Net Sales(x)	1.86	1.56	1.92	1.57	2.3	1.77	1.75	0.96	1.36	2.88	2.06
EV/Core EBITDA(x)	6.44	5.84	9.1	7.93	11.54	9.33	9.28	5.22	7.14	16.17	15.87
Net Sales Growth(%)	-6.7	25.56	5.14	6.17	9.54	27.83	22.65	-5.18	14.14	12.92	4.13
EBIT Growth(%)	-20.87	78.72	-27.89	-3.67	11.38	24.95	29.2	-13.74	35.55	2.95	-38.56
PAT Growth(%)	-45.16	153.12	-36.77	1.97	64.36	14.05	33.47	-18.08	57.68	20.55	-51.16
EPS Growth(%)	-45.16	153.12	-36.77	1.97	64.36	14.04	33.47	-18.08	57.68	20.55	-51.16
Debt/Equity(x)	1.7	1.37	1.28	1.1	0.99	0.95	0.87	0.79	0.65	0.63	0.66
Current Ratio(x)	0.81	1.06	0.97	1.23	1.29	1.21	1.35	1.27	1.32	1.24	1.4
Quick Ratio(x)	0.3	0.41	0.38	0.5	0.73	0.72	0.79	0.79	0.94	0.84	0.94
Interest Cover(x)	1.55	2.44	2	1.85	2.66	3.27	3.55	3.41	6.7	8	3.19
Total Debt/Mcap(x)	0.89	0.71	0.48	0.52	0.34	0.38	0.31	0.75	0.34	0.14	0.22

Hikal Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	68.77	68.77	68.77	68.77	68.83	68.85	68.85	68.85	68.85	68.85
FII	6.91	6.92	3.91	4.27	4.4	4.56	4.56	4.81	6.13	6.55
DII	0.38	0.88	0.89	1.37	1.57	2.19	2.78	3.12	3.15	3.53
Public	23.93	23.42	26.43	25.59	25.21	24.4	23.8	23.22	21.86	21.07
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	8.48	8.48	8.48	8.48	8.49	8.49	8.49	8.49	8.49	8.49
FII	0.85	0.85	0.48	0.53	0.54	0.56	0.56	0.59	0.76	0.81
DII	0.05	0.11	0.11	0.17	0.19	0.27	0.34	0.38	0.39	0.44
Public	2.95	2.89	3.26	3.16	3.11	3.01	2.93	2.86	2.7	2.6
Others	0	0	0	0	0	0	0	0	0	0
Total	12.33	12.33	12.33	12.33	12.33	12.33	12.33	12.33	12.33	12.33

Pros

Cons

Company has a low return on equity of 13% over the last 3 years.
Debtor days have increased from 87.68 to 92.7days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Hikal News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Hikal

Add Watchlist

Hikal Research see more...

Overview Inc. Year: 1988Industry: Pharmaceuticals & Drugs

Hikal Share Price

Alert Data

Quarterly Price

Peer Comparison

Hikal Quarterly Results

Hikal Profit & Loss

Growth Rates

Hikal Balance Sheet

Hikal Cash Flow

Hikal Ratios

Hikal Shareholding Pattern

Hikal News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!